Bu sayfada
ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 5, 2026
$19,95
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$19,5952 haftanın en düşüğü
$30,9652 haftanın en yükseği
Piyasa Değeri (MRQ)
$3.43B
P/E (TTM)
8.9
Hisse Başına Kâr (TTM)
$2.23
Gelir (TTM)
$1.14B
rozetleriniz
52 Haftlık Aralık
$20–$31
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$32
P/E
8.9
ROE
35.7%
Net Kâr Marjı
33.4%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
ACAD Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$19.95
Piyasa Değeri (MRQ)
$3.43B
P/E (TTM)
8.9
Hisse Başına Kâr (TTM)
$2.23
Gelir (TTM)
$1.14B
ROE (TTM)
35.7%
52 Haftlık Aralık
$20–$31
ACAD Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
ACADIA Pharmaceuticals Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar796
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$1.07B2016-12-31 → 2025-12-31
Hisse Başına Kâr$2.302020-12-31 → 2025-12-31
Serbest Nakit Akışı$105M2016-12-31 → 2025-12-31
Net kar marjı33.4%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | ACAD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 8.95Y ort. ≈-18.7 | ≈-18.7 | 13.8 | Düşük değerli | |
| F/S (TTM) | 3.05Y ort. ≈5.5 | ≈5.5 | 11.9 | Düşük değerli | |
| F/D (MRQ) | 2.65Y ort. ≈6.6 | ≈6.6 | 3.4 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | 23.65Y ort. ≈64.0 | ≈64.0 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 21.45Y ort. ≈63.4 | ≈63.4 | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 2.95Y ort. ≈7.3 | ≈7.3 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | ACAD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 7.6%5Y ort. ≈-10.9% | ≈-10.9% | 12.5% | Aynı seviyede | |
| EBITDA Margin (FAVÖK Marjı) | 9.8%5Y ort. ≈-10.9% | ≈-10.9% | 12.5% | Aynı seviyede | |
| Vergi Öncesi Kar Marjı (TTM) | 10.7%5Y ort. ≈-8.6% | ≈-8.6% | 16.4% | Aynı seviyede | |
| Net Kâr Marjı (TTM) | 33.4%5Y ort. ≈-4.9% | ≈-4.9% | 10.2% | Aynı seviyede | |
| ROA (TTM) | 25.6%5Y ort. ≈-2.7% | ≈-2.7% | -7.4% | En üst düzey | |
| ROE (TTM) | 35.7%5Y ort. ≈-5.1% | ≈-5.1% | -10.7% | En üst düzey | |
| ROIC | 24.0%5Y ort. ≈-11.4% | ≈-11.4% | -3.0% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | ACAD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 3.45Y ort. ≈3.8 | ≈3.8 | 6.5 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 1.15Y ort. ≈1.4 | ≈1.4 | 5.0 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | ACAD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 11.9%5Y ort. ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 27.5%5Y ort. ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 19.4% | · | · | · | |
| EPS YoY (EPS YB) | 69.1% | · | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 72.7% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | ACAD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.85Y ort. ≈0.9 | ≈0.9 | 0.4 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 0.95Y ort. ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 9.75Y ort. ≈9.1 | ≈9.1 | 10.5 | Aynı seviyede | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.3M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
228.8%
Sonraki Rapor
Kas 03, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 11, 2026 | $0.18 | $0.06 | 207.2% |
| 31 Mart 2026 | May 13, 2026 | $0.02 | $0.06 | -68.4% |
| 31 Aralık 2025 | $1.60 | $0.14 | 1044.5% | |
| 30 Eylül 2025 | $0.42 | $0.15 | 178.1% | |
| 30 Haziran 2025 | $0.16 | $0.14 | 14.4% | |
| 31 Mart 2025 | $0.11 | $0.11 | -3.2% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $1.07B | $958M | $726M | $517M | $484M |
| Brüt Kâr Marjı % | · | · | 94.3% | 98.0% | 97.8% |
| Faaliyet Kâr Marjı % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Net Gelir | $391M | $226M | $-61M | $-216M | $-168M |
| Seyreltilmiş Hisse Başı Kâr | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Cari Oran | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $105M | $157M | $17M | $-114M | $-127M |
Kurumsal Sahipler (13F) 385 dosya · $4.7B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
385
Tutulan Değer
$4.7B
Yeni pozisyonlar
49
Çıkan pozisyonlar
36
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 49 (-4 önceki Ç'ye göre) | 36 (+8 önceki Ç'ye göre) | 135 (+15 önceki Ç'ye göre) | 115 (-7 önceki Ç'ye göre) | +4.6M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1.085.696.471 | 42.912.904 | 23,31% | Hisse senetleri |
| BlackRock, Inc. | $569.633.876 | 22.515.173 | 12,23% | Hisse senetleri |
| VANGUARD GROUP INC | $404.762.192 | 15.153.957 | 8,69% | Hisse senetleri |
| STATE STREET CORP | $229.628.164 | 9.076.212 | 4,93% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223.612.785 | 8.838.450 | 4,80% | Hisse senetleri |
| RTW INVESTMENTS, LP | $180.756.457 | 7.144.524 | 3,88% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $145.822.875 | 5.763.750 | 3,13% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $93.482.749 | 3.694.988 | 2,01% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $84.977.229 | 3.358.129 | 1,82% | Hisse senetleri |
| Palo Alto Investors LP | $72.461.629 | 2.864.096 | 1,56% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $65.276.910 | 2.580.115 | 1,40% | Hisse senetleri |
| Qube Research & Technologies Ltd | $61.899.233 | 2.446.610 | 1,33% | Hisse senetleri |
| Point72 Asset Management, L.P. | $61.559.150 | 2.433.168 | 1,32% | Hisse senetleri |
| CITADEL ADVISORS LLC | $55.209.078 | 2.182.177 | 1,19% | Hisse senetleri |
| Pictet Asset Management Holding SA | $50.146.450 | 1.983.198 | 1,08% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49.826.959 | 1.969.445 | 1,07% | Hisse senetleri |
| MARSHALL WACE, LLP | $44.650.402 | 1.764.838 | 0,96% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $42.957.806 | 1.697.937 | 0,92% | Hisse senetleri |
| BRAIDWELL LP | $41.653.895 | 1.646.399 | 0,89% | Hisse senetleri |
| NORGES BANK | $41.069.692 | 1.623.308 | 0,88% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $36.386.409 | 1.438.198 | 0,78% | Hisse senetleri |
| NORTHERN TRUST CORP | $34.595.776 | 1.367.422 | 0,74% | Hisse senetleri |
| Nuveen, LLC | $34.109.259 | 1.348.192 | 0,73% | Hisse senetleri |
| Artisan Partners Limited Partnership | $33.525.890 | 1.325.134 | 0,72% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $32.899.740 | 1.300.385 | 0,71% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $32.449.679 | 1.282.596 | 0,70% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30.520.301 | 1.206.336 | 0,66% | Hisse senetleri |
| Allspring Global Investments Holdings, LLC | $28.540.663 | 1.132.566 | 0,61% | Hisse senetleri |
| Rockefeller Capital Management L.P. | $25.690.127 | 1.015.420 | 0,55% | Hisse senetleri |
| MORGAN STANLEY | $23.949.976 | 946.639 | 0,51% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $23.452.898 | 926.992 | 0,50% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $23.082.961 | 912.370 | 0,50% | Hisse senetleri |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21.642.506 | 855.435 | 0,46% | Hisse senetleri |
| Invesco Ltd. | $20.504.689 | 810.462 | 0,44% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $19.966.658 | 789.196 | 0,43% | Hisse senetleri |
| Bank of New York Mellon Corp | $19.243.919 | 760.629 | 0,41% | Hisse senetleri |
| Allianz Asset Management GmbH | $19.157.034 | 757.195 | 0,41% | Hisse senetleri |
| PANAGORA ASSET MANAGEMENT INC | $17.985.922 | 710.906 | 0,39% | Hisse senetleri |
| Fisher Asset Management, LLC | $17.690.535 | 699.230 | 0,38% | Hisse senetleri |
| FRED ALGER MANAGEMENT, LLC | $16.409.858 | 648.611 | 0,35% | Hisse senetleri |
| RICE HALL JAMES & ASSOCIATES, LLC | $15.657.841 | 618.887 | 0,34% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $15.348.144 | 606.536 | 0,33% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $14.925.077 | 589.924 | 0,32% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14.771.456 | 583.852 | 0,32% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $13.225.551 | 522.749 | 0,28% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.903.000 | 510.000 | 0,28% | Hisse senetleri |
| GLENMEDE TRUST CO NA | $12.360.212 | 488.546 | 0,27% | Hisse senetleri |
| Hudson Bay Capital Management LP | $11.764.500 | 465.000 | 0,25% | Hisse senetleri |
| UBS Group AG | $11.639.341 | 460.053 | 0,25% | Hisse senetleri |
| JUPITER ASSET MANAGEMENT LTD | $11.599.190 | 458.466 | 0,25% | Hisse senetleri |
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 başvurular | 26 Şubat 2026 | 25,40% | Değişiklik | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 başvurular | 06 Haziran 2013 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 02 Mayıs 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 02 Mayıs 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 02 Mayıs 2005 | · | İlk başvuru | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 Nisan 2005 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 42 içeriden öğrenenler · 24 yöneticiler · 21 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | 24 Mart 2026 M | 14.803 | 0 | 1 | $-249.932 |
| Stephen Davis | CEO | 19 Ağustos 2024 S | 186.555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 Şubat 2015 M | 115.549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 06 Ağustos 2026 M | 67.828 | 0 | 9 | $-1.126.027 |
| Elena Ridloff | EVP and CFO | 29 Nisan 2021 M | 10.553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 Ekim 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 04 Nisan 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 Kasım 2022 M | 61.234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 Haziran 2006 S | 317.756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 17 Kasım 2024 M | 62.105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 Temmuz 2026 M | 18.994 | 0 | 3 | $-506.411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 Haziran 2026 S | 13.088 | 0 | 8 | $-602.789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 24 Mart 2026 M | 11.280 | 0 | 2 | $-245.022 |
| Thomas Garner | EVP, Chief Commercial Officer | 06 Mart 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | 06 Ocak 2024 M | 46.901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 Şubat 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 06 Ocak 2021 M | 8.059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 Ekim 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 Nisan 2018 A | 83.734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 08 Mart 2017 A | 1.671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 Mart 2015 A | 18.550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 08 Temmuz 2009 M | 20.000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 07 Mart 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 Mart 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 32.908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 33.489 | 0 | 0 | $0 |
| Jonathan Poole | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 2.010 | 0 | 0 | $0 |
| James M Daly | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 12.148 | 0 | 1 | $-671.100 |
| Laura Brege | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 23.202 | 0 | 0 | $0 |
| Edmund Harrigan | Yönetim kurulu üyesi | 29 Mayıs 2026 A | 43.148 | 0 | 0 | $0 |
| Daniel B Soland | Yönetim kurulu üyesi | 29 Mayıs 2025 A | 44.041 | 0 | 0 | $0 |
| Mary Ann Gray | Yönetim kurulu üyesi | 07 Haziran 2016 M | 149.476 | 0 | 0 | $0 |
| Leslie L Iversen | Yönetim kurulu üyesi | 18 Nisan 2016 M | 36.127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Yönetim kurulu üyesi | 11 Ağustos 2015 M | 17.000 | 0 | 0 | $0 |
| William Mcdowall Wells | Yönetim kurulu üyesi | 15 Haziran 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Yönetim kurulu üyesi | 15 Haziran 2015 A | 8.500 | 0 | 0 | $0 |
| Michael T Borer | Yönetim kurulu üyesi | 15 Haziran 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Yönetim kurulu üyesi | 12 Haziran 2009 A | 14.364 | 0 | 0 | $0 |
| Alan G Walton | Yönetim kurulu üyesi | 12 Haziran 2009 A | 25.979 | 0 | 0 | $0 |
| Martien Van Osch | Yönetim kurulu üyesi | 10 Haziran 2005 A | 1.168.892 | 0 | 0 | $0 |
| GORDON CARL L | Yönetim kurulu üyesi | 20 Nisan 2005 A | 774.006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | 20 Ekim 2008 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 59 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,92% | 13.265 SH | 11 Eylül 2026 | Günlük |
| PBE · Invesco Exchange-Traded Fund Trust | 1,84% | 383.853 SH | 02 Ekim 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,69% | 64.350 NS | 31 Temmuz 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,40% | 122.788 SH | 02 Ekim 2026 | Günlük |
| RZG · Invesco Exchange-Traded Fund Trust | 0,96% | 57.480 SH | 02 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,71% | 134.777 NS | 31 Temmuz 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,62% | 14.725 NS | 31 Temmuz 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150.827 SH | 19 Ağustos 2026 | Günlük |
| IBB · iShares Trust | 0,35% | 1.293.913 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,24% | 1.215.092 SH | 11 Eylül 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,23% | 12.181 SH | 02 Ekim 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,20% | 1.841 NS | 31 Temmuz 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137.860 SH | 19 Ağustos 2026 | Günlük |
| BKSE · BNY Mellon ETF Trust | 0,19% | 6.256 NS | 31 Temmuz 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443.221 SH | 19 Ağustos 2026 | Günlük |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,17% | 19.976 SH | 02 Ekim 2026 | Günlük |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,16% | 36.279 NS | 31 Temmuz 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 34.493 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3.296.450 SH | 11 Eylül 2026 | Günlük |
| ISCG · iShares Trust | 0,12% | 40.348 SH | 11 Eylül 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,10% | 137.841 SH | 02 Ekim 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741.237 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,09% | 559.090 NS | 31 Temmuz 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.699.377 SH | 19 Ağustos 2026 | Günlük |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 40.712 NS | 31 Temmuz 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 52.513 SH | 02 Ekim 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 10.893 NS | 31 Temmuz 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,05% | 2.295 NS | 31 Temmuz 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54.681 NS | 31 Temmuz 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7.263 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.457.036 SH | 19 Ağustos 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2.944.095 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,04% | 346.329 SH | 19 Ağustos 2026 | Günlük |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.154 SH | 02 Ekim 2026 | Günlük |
| WSML · iShares Trust | 0,04% | 11.751 SH | 11 Eylül 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 4.009 SH | 02 Ekim 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,02% | 5.018 NS | 31 Temmuz 2026 | N-PORT |
| ISCF · iShares Trust | 0,02% | 13.099 SH | 11 Eylül 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,02% | 113.182 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348.929 NS | 31 Temmuz 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,02% | 103.974 NS | 31 Temmuz 2026 | N-PORT |
| SCZ · iShares Trust | 0,02% | 238.968 SH | 09 Eylül 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,01% | 16.150 NS | 31 Temmuz 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 28.150 SH | 19 Ağustos 2026 | Günlük |
| DFAU · Dimensional ETF Trust | 0,01% | 39.121 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.516 SH | 10 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 161.527 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 35.634 NS | 31 Temmuz 2026 | N-PORT |
| IEFA · iShares Trust | 0,00% | 240.578 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.075.731 SH | 19 Ağustos 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 100.076 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.781 SH | 19 Ağustos 2026 | Günlük |
| IJR · iShares Trust | · | 7.728.763 SH | 10 Eylül 2026 | Günlük |
| IJT · iShares Trust | · | 1.198.794 SH | 09 Eylül 2026 | Günlük |
| XJR · iShares Trust | · | 17.544 SH | 31 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 5.636 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 221.806 SH | 11 Eylül 2026 | Günlük |
| SMMV · iShares Trust | · | 16.924 SH | 19 Ağustos 2026 | Günlük |
ACAD Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 27 analist
AL
Medyan hedef
$33.00
+65,4%
7 25,9%
Güçlü Al
14 51,9%
Al
5 18,5%
Tut
1 3,7%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
19 analist · 2026-09-29Ortalama hedef $32.16 +61,2%
Şimdi
Mevcut fiyat $19.95
Düşük$17.00
Ortalama$32.16
Yüksek$49.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Son Haberler Bu şirketten bahseden son manşetler
İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri
BLUECHIP_DIP
Süresi Doldu
risk 1
ödül 5,00
giriş
$21.20
R:R 5,00
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 4,79
giriş
$21.86
R:R 4,79
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 4,99
giriş
$22.45
R:R 4,99
Şu anda açık sinyal yok — hiçbir kart dolu değil ve bu dürüstçe.
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026